Sihuan Pharmaceutical Holdings Stock Current Liabilities
Sihuan Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Sihuan Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sihuan Pink Sheet. The fundamental analysis module provides a way to measure Sihuan Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sihuan Pharmaceutical pink sheet.
Sihuan |
Sihuan Pharmaceutical Holdings Company Current Liabilities Analysis
Sihuan Pharmaceutical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Sihuan Pharmaceutical Current Liabilities | 1.51 B |
Most of Sihuan Pharmaceutical's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sihuan Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Sihuan Pharmaceutical Holdings has a Current Liabilities of 1.51 B. This is 13.54% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current liabilities for all United States stocks is 80.83% higher than that of the company.
Sihuan Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sihuan Pharmaceutical's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sihuan Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sihuan Pharmaceutical by comparing valuation metrics of similar companies.Sihuan Pharmaceutical is currently under evaluation in current liabilities category among its peers.
Sihuan Fundamentals
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 3.29 B | |||
| Gross Profit | 2.45 B | |||
| EBITDA | 914.73 M | |||
| Net Income | 416.51 M | |||
| Cash And Equivalents | 5.25 B | |||
| Cash Per Share | 0.56 X | |||
| Total Debt | 844.75 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 2.43 X | |||
| Book Value Per Share | 0.78 X | |||
| Cash Flow From Operations | 665.29 M | |||
| Earnings Per Share | 0.01 X | |||
| Number Of Employees | 3.9 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 14.5 B | |||
| Retained Earnings | 5.54 B | |||
| Working Capital | 4.66 B | |||
| Current Asset | 6.17 B | |||
| Current Liabilities | 1.51 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 14.5 B | |||
| Last Dividend Paid | 0.014 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets |